Nasdaq: NBTX

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41)…

2 months ago

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French…

3 months ago